Jazz Pharmaceuticals PLC (JAZZ)vsVertex Pharmaceuticals Inc (VRTX)
JAZZ
Jazz Pharmaceuticals PLC
$238.57
-0.62%
HEALTHCARE · Cap: $14.48B
VRTX
Vertex Pharmaceuticals Inc
$446.83
+1.24%
HEALTHCARE · Cap: $107.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 175% more annual revenue ($12.22B vs $4.44B). VRTX leads profitability with a 35.5% profit margin vs 0.7%. JAZZ appears more attractively valued with a PEG of 0.96. VRTX earns a higher WallStSmart Score of 68/100 (B-).
JAZZ
Buy56
out of 100
Grade: C
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+52.2%
Fair Value
$347.46
Current Price
$238.57
$108.89 discount
Margin of Safety
+53.1%
Fair Value
$952.53
Current Price
$446.83
$505.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Strong operational efficiency at 23.5%
19.1% revenue growth
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
3.2% earnings growth
ROE of 0.7% — below average capital efficiency
0.7% margin — thin
Elevated debt levels
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JAZZ
The strongest argument for JAZZ centers on PEG Ratio, Operating Margin, Revenue Growth. Revenue growth of 19.1% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : JAZZ
The primary concerns for JAZZ are EPS Growth, Return on Equity, Profit Margin. A P/E of 1921.3x leaves little room for execution misses. Thin 0.7% margins leave little buffer for downturns.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
JAZZ profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
JAZZ carries more volatility with a beta of 0.33 — expect wider price swings.
JAZZ is growing revenue faster at 19.1% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 56/100), backed by strong 35.5% margins. JAZZ offers better value entry with a 52.2% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Jazz Pharmaceuticals PLC
HEALTHCARE · BIOTECHNOLOGY · USA
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?